Technical Analysis for BLUE - bluebird bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.98 | -0.90% | -0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| 20 DMA Support | Bullish | -0.90% | |
| Crossed Above 50 DMA | Bullish | -0.90% | |
| Bollinger Band Squeeze | Range Contraction | -0.90% | |
| 50 DMA Resistance | Bearish | 2.80% | |
| Crossed Above 20 DMA | Bullish | 2.80% | |
| Bollinger Band Squeeze | Range Contraction | 2.80% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| Fell Below 50 DMA | about 7 hours ago |
| 50 DMA Support | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Down 2 % | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/06/2024
bluebird bio, Inc. Description
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Dystrophy Human Diseases Summit Childhood Genetic Genealogy Sickle Cell Disease Thalassemia Iglo Oncology Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.53 |
| 52 Week Low | 0.845 |
| Average Volume | 6,478,437 |
| 200-Day Moving Average | 1.86 |
| 50-Day Moving Average | 0.96 |
| 20-Day Moving Average | 0.95 |
| 10-Day Moving Average | 0.94 |
| Average True Range | 0.08 |
| RSI (14) | 51.46 |
| ADX | 11.53 |
| +DI | 20.67 |
| -DI | 16.63 |
| Chandelier Exit (Long, 3 ATRs) | 0.82 |
| Chandelier Exit (Short, 3 ATRs) | 1.08 |
| Upper Bollinger Bands | 1.03 |
| Lower Bollinger Band | 0.87 |
| Percent B (%b) | 0.67 |
| BandWidth | 16.75 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0073 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.05 | ||||
| Resistance 3 (R3) | 1.05 | 1.03 | 1.04 | ||
| Resistance 2 (R2) | 1.03 | 1.01 | 1.03 | 1.03 | |
| Resistance 1 (R1) | 1.00 | 1.00 | 1.02 | 1.00 | 1.03 |
| Pivot Point | 0.98 | 0.98 | 0.99 | 0.98 | 0.98 |
| Support 1 (S1) | 0.95 | 0.96 | 0.97 | 0.95 | 0.92 |
| Support 2 (S2) | 0.93 | 0.95 | 0.93 | 0.92 | |
| Support 3 (S3) | 0.90 | 0.93 | 0.91 | ||
| Support 4 (S4) | 0.90 |
